N-Cyano-N-Methyl-Ethanimidamide

We are N-Cyano-N-Methyl-Ethanimidamide CAS:56563-12-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Related News: China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.2,6-Dimethylpyrazine Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.2-Chloroethyl Ethyl Ether CAS:628-34-2 Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.18063-03-1 From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.However, compared with the 60-70% refinement rate in developed economies such as North America, Western Europe, and Japan, China is still only equivalent to the level of the United States in the 1980s. There is still a lot of room for improvement in China’s refinement rate. period.